Get the Stockscreener App
18.70
10.72%
1.81
Pre-market:
16.00
-2.70
-14.44%
Septerna Inc stock is traded at $18.70, with a volume of 355.37K.
It is up +10.72% in the last 24 hours and down -22.98% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.
See More
Previous Close:
$16.89
Open:
$17.02
24h Volume:
355.37K
Relative Volume:
1.43
Market Cap:
$830.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+10.26%
1M Performance:
-22.98%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.75
$19.13
1-Week Range:
$16.40
$19.13
52-Week Range:
$15.86
$28.99
Septerna Inc Stock (SEPN) Company Profile
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
18.70 | 830.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
Septerna Inc Stock (SEPN) Latest News
Septerna to Introduce Groundbreaking GPCR Drug Discovery Innovations - Defense World
Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened - Defense World
Septerna (NASDAQ:SEPN) Sets New 12-Month LowTime to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Trading Down 8.5%Here's Why - MarketBeat
Septerna (NASDAQ: SEPN) Appoints Gil Labrucherie as Chief Financial Officer - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Marketscreener.com
Septerna appoints new CFO to bolster financial strategy By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Shares Gap DownTime to Sell? - MarketBeat
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Manila Times
Septerna Brings in Gil Labrucherie as Finance Chief - MarketWatch
Septerna appoints new CFO to bolster financial strategy - Investing.com
Septerna Names Biotech Veteran Gil Labrucherie as CFO, Brings $1.5B Capital Raising Success - StockTitan
Septerna (NASDAQ:SEPN) Trading 7.7% HigherShould You Buy? - MarketBeat
Septerna initiated with an Overweight at JPMorgan - MSN
Septerna (NASDAQ:SEPN) Shares Down 5%Time to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy? - Defense World
Septerna (NASDAQ:SEPN) Trading Up 8.4%Time to Buy? - MarketBeat
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present GPCR Drug Discovery Pipeline at J.P. Morgan Healthcare Conference 2025 - StockTitan
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):